The premise behind the work rests on a deceptively simple observation. Every biological phenomenon unfolds in physical space and time, involving continuous changes in shape, quantity and matter. Those changes can be described mathematically, and once they are, researchers gain a tool that observation alone cannot provide. “Every biological phenomenon occurs in the physical world—in space and time—and involves changes in shape, quantity and matter,” Yarahmadian explained. “Because of its abstract power, mathematics allows us to uncover patterns, test hypotheses and make predictions that may not be possible through observation alone.” In other words, a well-built model can compress years of trial-and-error experimentation into a set of equations whose behavior can be explored on a computer in hours.

The biological target of the model is amyloid-beta, a small protein fragment that, in a healthy brain, is produced and cleared in a carefully balanced cycle. In Alzheimer’s disease, that balance tips. Individual amyloid-beta peptides begin to misfold and cling to one another, first forming small soluble clusters called oligomers, then longer protofibrils, and finally the insoluble fibrillar plaques that accumulate between neurons. This aggregation cascade is not a single reaction but a branching network of processes, each with its own rate, and each potentially influenced by the chemical environment surrounding the protein. That complexity is precisely what makes the disease so difficult to study experimentally, and precisely where mathematical modeling earns its keep.

Metal ions enter the picture because of a long-standing and growing body of biochemical evidence that copper and zinc bind directly to amyloid-beta and can dramatically alter its aggregation behavior. Depending on concentration, oxidation state and conditions, these metals can accelerate the formation of aggregates, stabilize particular intermediate species, or change the morphology of the fibrils that ultimately form. Because copper and zinc are normally present in the brain and are involved in synaptic function, their interaction with amyloid-beta is not an exotic curiosity but a plausible contributor to disease progression. Capturing that interplay quantitatively, however, requires a model that tracks not only the protein’s aggregation states but also the binding and unbinding of metal ions at each stage—a considerable mathematical challenge.

Yarahmadian’s framework does exactly that. It simulates the chain of reactions through which metals such as copper and zinc may influence amyloid-beta aggregation and plaque formation, coupling the kinetics of protein clustering with the dynamics of metal-ion binding. Crucially, the model was designed to do more than describe the disease process; it also allows researchers to examine two potential therapeutic strategies for disrupting it. The first is chelation therapy, in which molecules would be deployed to sequester excess metal ions and strip them away from amyloid-beta, potentially slowing or reversing the aggregation they promote. The second involves inhibitory approaches that act directly on the aggregation pathway itself, interfering with the steps by which peptides assemble into larger structures. By adjusting parameters that represent these interventions, the model can explore how different treatment strategies might shift the balance of the system over time.

Building a model is one thing; proving that it means anything is another. A set of equations can be internally consistent and still bear no relationship to biological reality, so the team subjected their framework to a demanding test. They compared the model’s output against experimental data generated by atomic force microscopy, a technique capable of imaging aggregates at nanometer scale and revealing the size and structure of the microscopic clusters that amyloid-beta forms in the laboratory. This validation step is where many theoretical models falter, but here the results were encouraging: the model successfully reproduced the patterns observed in the experimental measurements.

That agreement matters more than it might first appear. It demonstrates that the model is not merely a theoretical calculation but a tool that can accurately predict real-world behavior, giving scientists greater confidence in understanding how aggregates form and, potentially, how they might be controlled. In practical terms, a validated model becomes a virtual laboratory. Researchers can ask questions that would be expensive, slow or ethically fraught to answer with real experiments: What happens if metal concentrations rise in a particular brain region? At what point in the aggregation cascade would a chelation therapy have the greatest effect? Which step in the reaction network is the most influential lever, and therefore the most promising drug target? The model cannot answer these questions definitively, but it can rank hypotheses and point experimentalists toward the tests most likely to be informative.

“Mathematics does not replace laboratory or clinical research; it complements it by helping us understand the larger system, identify the most influential mechanisms and guide future experiments,” Yarahmadian said. That division of labor is increasingly common across the life sciences. As biological datasets grow larger and the systems under study grow more intricate, the ability to formalize hypotheses mathematically and test them computationally has become a genuine partner to the bench and the clinic rather than an afterthought. In Alzheimer’s research specifically, where more than a hundred candidate drugs have failed in clinical trials over recent decades, tools that can narrow the search space before trials begin carry obvious value.

“What drew me to Alzheimer’s research is the combination of its profound human impact and its extraordinary biological complexity,” Yarahmadian said. “My goal is to use mathematical modeling to identify important mechanisms and generate insights that may help guide future experimental and therapeutic research.” The study, published on 20 August 2026 under the title describing metal-ion-mediated amyloid-beta aggregation and a mathematical model of chelation and inhibitory therapies, was classified as computational simulation and modeling, and its authors declared no conflicts of interest. The work builds on Yarahmadian’s broader research program into mathematical models of Alzheimer’s disease, positioning the Mississippi State group within a growing community of applied mathematicians tackling neurodegeneration.

The road from a validated model to a therapy is, of course, long. Mathematical frameworks do not shrink tumors or restore memories; their contribution is to sharpen the questions and reduce the guesswork. Yet in a field where the underlying mechanisms remain fiercely debated—where amyloid-beta’s role itself has been questioned after high-profile drug setbacks—quantitative tools that connect metal chemistry, protein aggregation and therapeutic intervention offer something rare: a way to see the system whole. If the model’s predictions continue to align with laboratory observations, the equations developed in Starkville may help decide where the next generation of Alzheimer’s experiments, and perhaps eventually treatments, should look. It would be a striking outcome if part of the answer to one of medicine’s hardest problems turned out to be written, at least in part, in mathematics.

Subject of Research: Mathematical modeling of metal-ion-mediated amyloid-beta aggregation and chelation therapies in Alzheimer's disease

Article Title: Solving Alzheimer’s with math? Researcher explores the possibilities

Article References: Solving Alzheimer’s with math? Researcher explores the possibilities. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Alzheimer's disease, mathematical modeling, amyloid-beta, copper, zinc, chelation therapy, plaque formation, computational biology, Mississippi State University, Bulletin of Mathematical Biology, atomic force microscopy, drug targets

Wilson disease is caused by inherited loss-of-function mutations in the ATP7B gene, which encodes a copper-transporting ATPase responsible for loading copper onto ceruloplasmin in the liver and for excreting surplus copper into bile. When ATP7B fails, dietary copper that would normally leave the body through the biliary route instead accumulates in hepatocytes, eventually spilling into the bloodstream and depositing in the brain, cornea, kidneys and other organs. Clinical presentation is notoriously variable, ranging from acute liver failure in children and young adults to tremor, dystonia, psychiatric disturbance and cognitive decline later in life. The classic Kayser-Fleischer rings in the cornea remain one of the most recognizable diagnostic signs, but the underlying cellular events that convert copper overload into organ failure have remained only partially mapped.

The review emphasizes that copper’s dual role as an essential cofactor and a potent toxin hinges on concentration and chemical speciation. In controlled amounts, copper supports enzymes involved in respiration, antioxidant defense, iron metabolism, neurotransmitter synthesis and connective tissue cross-linking. In excess, particularly in the loosely bound, labile form that accumulates when buffering proteins such as metallothioneins are overwhelmed, copper catalyzes the generation of reactive oxygen species through Fenton-like chemistry. This oxidative burst damages lipids, proteins and DNA, and it is the mitochondria, the cell’s energy factories and major sites of copper-sensitive respiratory function, that emerge as a primary battleground in the disease process.

Mitochondrial dysfunction occupies a central position in the pathogenic model the authors assemble. Copper overload impairs the respiratory chain, disrupts mitochondrial membrane potential, distorts the ultrastructure of cristae and interferes with the metabolic enzymes that carry out the citric acid cycle and oxidative phosphorylation. Studies in animal models of Wilson disease, including the toxic milk mouse and the Long-Evans Cinnamon rat, have documented mitochondrial swelling and respiratory defects that precede overt liver failure. In patients, mitochondrial abnormalities have been observed in hepatocytes and in neural tissue, providing a mechanistic bridge between the biochemical burden of copper and the energetic collapse that marks end-stage disease. Because mitochondria also serve as decision-making hubs for cell death signaling, their compromise does not merely reduce energy output; it actively initiates the programs that dismantle the cell.

Perhaps the most consequential theme in the review is the concept of regulated cell death, the family of genetically encoded, signalable demise pathways that include apoptosis, necroptosis, ferroptosis and the recently described copper-dependent process known as cuproptosis. Classical descriptions of copper toxicity in Wilson disease leaned heavily on nonspecific necrosis, but the field now recognizes that dying hepatocytes and neurons deploy ordered molecular machinery. Apoptosis, driven by mitochondrial outer membrane permeabilization and caspase activation, has been documented in copper-loaded liver tissue. Necroptosis, an inflammatory form of regulated death mediated by the RIPK1-RIPK3-MLKL axis, offers a plausible route by which copper-stressed liver tissue recruits immune cells and amplifies damage. Ferroptosis, an iron-dependent lipid peroxidation-driven death modality, is closely linked to the oxidative stress that copper overload generates, and glutathione depletion, a recurring biochemical finding in Wilson disease, removes a key cellular defense against it.

Cuproptosis deserves particular attention in this framework. Identified as a distinct form of regulated cell death, it depends on copper binding to lipoylated components of the tricarboxylic acid cycle, causing those proteins to aggregate and triggering proteotoxic stress that culminates in cell death. Because the pathway is intrinsically mitochondrial and metabolic, it connects the two other pillars of the review’s thesis: copper excess and mitochondrial dysfunction. Whether cuproptosis is the dominant death pathway in Wilson disease hepatocytes or one contributor among several remains an open question, and the authors are careful to frame it as a hypothesis-generating link rather than a settled fact. Still, the convergence is striking. A disease defined by copper retention, a cell death modality defined by copper sensitivity, and an organelle whose failure characterizes both.

The neurological dimension of Wilson disease adds another layer of complexity. The brain is exquisitely sensitive to metal imbalance, and copper accumulation in the basal ganglia and other regions contributes to the movement disorders and neuropsychiatric symptoms that define the neurologic form of the illness. Neurons face the same oxidative and mitochondrial threats as hepatocytes, but with less regenerative capacity and with additional vulnerabilities, including disruption of copper-dependent enzymes involved in neurotransmitter metabolism and myelination. The review highlights how glial cells, particularly astrocytes, participate in copper handling in the brain and how their dysfunction may propagate injury to neurons. Understanding whether the same regulated death pathways operate in neural tissue as in the liver is an important direction for future research, with direct implications for the roughly half of patients who present with or develop neurological disease.

Therapeutically, the framework has immediate relevance. Standard treatment for Wilson disease has rested for decades on two strategies: chelation therapy with drugs such as penicillamine and trientine, which bind copper and promote its urinary excretion, and zinc salts, which block intestinal copper absorption and induce metallothionein in enterocytes. These approaches are effective for many patients but are limited by side effects, the risk of neurological worsening during initial chelation, and the irreversibility of some established damage. The review’s synthesis suggests new targets. If mitochondrial dysfunction is a proximate driver of cell death, then mitochondria-protective agents, antioxidants and modulators of mitochondrial quality control could complement copper-lowering therapy. If specific death pathways such as necroptosis or ferroptosis are activated, their molecular regulators become candidate drug targets, an approach already being explored in other liver diseases. The authors also point to gene therapy and mRNA-based strategies aimed at restoring functional ATP7B, several of which are in preclinical and early clinical development, as interventions that address the root cause rather than downstream consequences.

Biomarker development is another area the review identifies as ripe for progress. Current monitoring relies on serum copper and ceruloplasmin, 24-hour urinary copper excretion and non-ceruloplasmin-bound copper measurements, none of which perfectly reflect intracellular copper burden or the activity of the death pathways that matter most in tissue. Reliable markers of mitochondrial injury, lipid peroxidation or regulated cell death activation in accessible biofluids would allow clinicians to gauge disease activity more precisely and to evaluate new therapies more efficiently. Research into copper-sensitive probes and imaging approaches may eventually permit noninvasive assessment of metal distribution in liver and brain, transforming both diagnosis and treatment monitoring.

The broader significance of the review extends beyond a single rare disease. Wilson disease has historically served as a model for understanding copper biology in general, and insights gained from it inform research on common conditions in which copper dysregulation has been implicated, including neurodegenerative disorders, cancer and non-alcoholic fatty liver disease. The recognition that metals can execute cells through dedicated death pathways has opened a field that now spans toxicology, cell biology and therapeutics. By situating Wilson disease within this landscape, the authors argue that the condition should be viewed not merely as a storage disorder to be drained, but as a systems-level failure of metal homeostasis, mitochondrial integrity and cell death control. For patients, the hope is that this integrated view will accelerate the translation of molecular discoveries into treatments that protect cells before the point of no return is crossed, preserving both liver function and the neurological health on which quality of life depends.

Subject of Research: Copper dyshomeostasis, mitochondrial dysfunction and regulated cell death pathways in Wilson disease

Article Title: Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease

Article References: Qian, N., Xi, H., Song, Y., Li, J., Yang, Y., Rao, Z., Zhai, S., He, W., Qin, G., Cheng, T., & Yang, W. (2026). Copper dyshomeostasis, mitochondrial dysfunction, and regulated cell death in Wilson disease. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03361-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03361-y

Keywords: Wilson disease, copper dyshomeostasis, ATP7B, mitochondrial dysfunction, cuproptosis, regulated cell death, apoptosis, necroptosis, ferroptosis, hepatic copper accumulation, chelation therapy, gene therapy